Synnovation Therapeutics
Chao Qi began their work experience in 2011 at Boston University, where they completed their PHD from September 2011 to September 2016. They then joined Incyte in October 2016 as a Research Investigator and was promoted to Senior Research Investigator in August 2018. In December 2020, Chao Qi became a Principal Investigator at Incyte before transitioning to their current role as an Associate Director at Synnovation Therapeutics in September 2021.
Chao Qi completed a Bachelor's Degree in Medicinal and Pharmaceutical Chemistry from Peking University Health Science Center, from 2007 to 2011. Following this, Chao Qi pursued a Doctor of Philosophy (Ph.D.) in Organic Chemistry at Boston University, from 2011 to 2016.
This person is not in any teams
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.